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Abstract
Background:With the large amount of pharmacological and biological knowledge available in literature, finding novel drug
indications for existing drugs using in silico approaches has become increasingly feasible. Typical literature-based
approaches generate new hypotheses in the form of protein-protein interactions networks by means of linking concepts
based on their cooccurrences within abstracts. However, this kind of approaches tends to generate too many hypotheses,
and identifying new drug indications from large networks can be a time-consuming process.
Methodology: In this work, we developed a method that acquires the necessary facts from literature and knowledge bases,
and identifies new drug indications through automated reasoning. This is achieved by encoding the molecular effects
caused by drug-target interactions and links to various diseases and drug mechanism as domain knowledge in AnsProlog,
a declarative language that is useful for automated reasoning, including reasoning with incomplete information. Unlike
other literature-based approaches, our approach is more fine-grained, especially in identifying indirect relationships for drug
indications.
Conclusion/Significance: To evaluate the capability of our approach in inferring novel drug indications, we applied our
method to 943 drugs from DrugBank and asked if any of these drugs have potential anti-cancer activities based on
information on their targets and molecular interaction types alone. A total of 507 drugs were found to have the potential to
be used for cancer treatments. Among the potential anti-cancer drugs, 67 out of 81 drugs (a recall of 82.7%) are indeed
known cancer drugs. In addition, 144 out of 289 drugs (a recall of 49.8%) are non-cancer drugs that are currently tested in
clinical trials for cancer treatments. These results suggest that our method is able to infer drug indications (original or
alternative) based on their molecular targets and interactions alone and has the potential to discover novel drug indications
for existing drugs.
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Introduction
The current model of drug discovery and development is
perceived as a costly and time-consuming process [1]. To reduce
the cost and shorten the duration for drug development, drug
repurposing, also known as drug repositioning, has become an
attractive alternative to traditional drug development aiming to
shorten the development process. Drug repurposing is the process
of finding a new indication for existing drug compounds. In other
words, it is a discovery process on how an existing drug compound
can be used for the treatment of diseases other than its original
indication. Reusing these drug compounds has the advantage of
bypassing many of the expensive steps of drug development, such
as in vitro and in vivo screening, chemical optimization,
toxicology, bulk manufacturing, formulation development. This
reduces cost and development risks, as well as shortens the typical
10–17 year process of drug development to 3–12 years [2]. The
best known success story of drug repositioning is the development
of sildenafil, a compound that was developed by Pfizer and
intended for the treatment of angina. Clinical trials of the drug
showed unexpected side effects that led to the treatment of erectile
dysfunction, and sildenafil became the blockbuster drug more
commonly known as ViagraH. Further studies and repositioning of
the drug compound showed yet another therapeutic indication for
treating pulmonary arterial hypertension, marketed as RevatioH.
This is due to the fact that sildenafil is an inhibitor of
phosphodiesterase-5 (PDE-5) proteins, and PDE-5 is known to
be expressed in pulmonary hypertensive lungs [3].
The main concept behind drug repurposing is that novel
drug indications can be identified based on the principle that
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the primary target of a drug can be associated with diseases
other than its original drug indication. In addition, as drugs can
act on multiple targets, secondary targets can be utilized for
novel drug indications as well. Several systematic approaches of
finding new uses for old drugs have been proposed. These
methods can be broadly classified into two categories: target
discovery based on chemical compound similarity [4] and
literature-based discovery [5]. Compound similarity has been
a popular approach to identify drug targets for drug repurpos-
ing. The assumption is that similar drug compounds have
similar targets so that targets that are not shared between a pair
of similar compounds can be identified as novel targets to the
other. By identifying new targets for existing compounds, new
drug indications can then be proposed. On the other hand,
typical text mining methods focus on the extraction of
knowledge such as protein-protein interactions from biomedical
literature. These text mining efforts including the BioCreAtIvE
challenge [6], a community effort that aims to advance the
development of biological knowledge extraction systems, focus
on the extraction of biological knowledge that is explicitly stated
in the literature. Literature-based discovery methods go a step
further by identifying relevant knowledge through text mining
so that new knowledge can be inferred from existing knowledge.
Swanson’s ABC Model [7] is a popular literature-based
discovery methodology that was proposed to link two concepts
through a commonly shared concept. Scientific concepts A and
C form a relationship when concept A cooccurs with concept B
in one publication while concepts B and C cooccur in another
publication. Variations of Swanson’s ABC models have been
described in the literature for the identification of indirect
relationships [8,9]. However, approaches based on cooccur-
rences of concepts within abstracts tend to generate too many
hypotheses. Another direction for network-based approaches
aims to uncover knowledge through the creation of biological
networks. STITCH [10] and ChemProt [11] are examples of
network-based approaches that take interactions extracted from
literature and integrates with data from biological knowledge
bases to create chemical compound-protein interaction net-
works. This kind of approach in linking the concepts does not
consider the inherent relationships between the pairs of concepts
such as interaction type and directionality of interactions, thus
leading to a large number of hypotheses. To handle large
networks that are generated by means of literature mining and
other data sources, visualization tools have been proposed to
assist the discovery of novel drug indications [12,13].
In this paper, we propose a new literature-based discovery
approach for drug repurposing that integrates facts from various
sources to infer novel indications by means of automated
reasoning. Our approach captures the various effects of drug-
target interactions inside cells as well as the molecular mechanisms
of diseases. Using cancer as an example, we utilized the wealth of
knowledge about cancer and encoded oncogenes and tumor
suppressors as well as cancer-related biological processes as the
domain knowledge for our method. Together with the protein-
protein interactions and gene-disease associations acquired from
the literature, our approach identified drugs that are potential
candidates for the treatment of cancer. By considering the
interaction types and their directionality and the domain
knowledge involved in the mechanism of action of drugs, our
approach aims to produce biologically meaningful hypotheses for
novel drug indications and can significantly reduce the number of
hypotheses as compared to previous text mining and literature-
based discovery approaches.
Methods
Our approach can be divided into three main components: (i)
the knowledge acquisition component; (ii) the knowledge representation
component; and (iii) the reasoning component. The knowledge acquisi-
tion component includes publicly available curated sources as well
as the relevant facts for the identification of drug indications
acquired using text mining. To automatically propose alternative
drug indications, it is necessary to first represent the mechanism of
drug action in the form of logic rules. With the facts acquired from
the knowledge acquisition component and the logic rules defined
in the knowledge representation component, the reasoning engine
utilizes the logic rules to find interactions that link drugs with the
corresponding drug indications.
Mechanism of Action of Drugs
The basic mechanism of drug action involves the activation or
inhibition of the function of drug targets that are responsible for
certain diseases, and this interaction translates into clinical effects
of the drug. One example is the drug levodopa, which is an agonist
that targets the dopamine receptors to increase dopamine levels for
the treatment of Parkinson’s disease [14]. Inhibition or activation
of drug targets such as oncogenes and tumor suppressors can also
trigger cancer-related biological processes and pathways. An
example of such drug action is erlotinib, an antagonist that targets
the oncogene known as the epidermal growth factor receptor
(EGFR) and alters the signal transduction in the EGFR signaling
pathway [15]. It is typical that a drug interacts with multiple
targets, in which the original indication is related to the primary
target. Alternative indications can be hypothesized through the
secondary targets and their corresponding roles in diseases. On the
other hand, a target can be involved in various diseases and
biological pathways. By studying the roles of the target in diseases
and pathways, alternative indications can be proposed through
deeper understanding of the targets.
Knowledge Acquisition
To identify novel drug indications, the first step of our approach
is to acquire various types of knowledge that are relevant to the
mechanism of action (MOA) of the drug. Such knowledge includes
(i) drug-target interactions; (ii) oncogenes and tumor suppressors;
(iii) genes involved in cancer-related biological processes; (iv) gene-
disease relations; (iv) protein-protein interactions. Table 1 provides
a summary of sources that are used to acquire knowledge for our
approach. DrugBank [16] was used as the source of knowledge for
drug-target relations, i.e. whether a drug is an antagonist or an
agonist for a drug target. Several sources are utilized as there is no
single source of complete knowledge on oncogenes and tumor
suppressors. Specifically UniProt (http://www.uniprot.org), En-
trez Gene (http://www.ncbi.nlm.nih.gov/gene) and CancerQuest
(http://www.cancerquest.org/oncogene-table and http://www.
cancerquest.org/tumor-suppressors-table) were considered in our
approach. For UniProt and Entrez Gene, the list of cancer genes
was obtained by using the keywords ‘‘oncogene’’ and ‘‘tumor
suppressor’’ as search criteria. Genes belonging to cancer-related
biological processes such as ‘‘cell proliferation’’, ‘‘apoptosis’’ and
‘‘angiogenesis’’ were obtained from the Gene Ontology annota-
tions (http://www.geneontology.org/GO.downloads.annotations.
shtm).
While databases such as PharmGKB [17] and IntAct [18] are
great resources for gene-disease relations and protein-protein
interactions, such databases are limited in terms of the coverage of
the literature due to the time-intensive process of manual curation.
More importantly, it is commonly the case that the type of the
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interactions is not captured in these databases. This becomes an
obstacle when the interactions from these databases are used in the
discovery of new knowledge. Suppose we know that a protein
interacts with an oncogene. The consequence of the interaction,
i.e. whether the function of the oncogene is activated or suppressed
due to the interaction, is an important factor when the interaction
is considered as part of the mechanism of a drug for treating
cancer. To capture the types of the interactions, our approach is to
utilize text mining so that appropriate interactions can be
identified efficiently from the literature.
Our text mining approach is to rely on grammatical structures
and keywords to capture the directionality and the types of the
interactions for the extraction of gene-disease relations and
protein-protein interactions. The parse tree query language (PTQL)
[19] is a suitable language that allows extraction patterns to be
defined over keywords and grammatical structures. PTQL is
a query language designed for information extraction over
a database of syntactic structures of text known as the parse tree
database (PTDB). Our latest version of the PTDB contains
a collection of 19 million Medline abstracts, and the Stanford
parser [20] is utilized to create parse trees of sentences. BANNER
[21] is used for the recognition of gene names from text, and the
recognized gene names are then mapped to official gene symbols
using GNAT [22]. By defining the keywords and extraction
patterns in the form of PTQL queries, it becomes possible to
extract the directionality and the types of interactions for gene-
disease relations and protein-protein interactions. Specifically, the
following types of interactions are extracted: (i) association of over-
or under-expressed genes with diseases (denoted as ,over2/
under-expressed p, associated with, d., where p corresponds to
a gene/protein name and d for a disease name); (ii) stimulation or
inhibition of proteins by other proteins (denoted as ,p1, induces/
inhibits, p2., where p1 and p2 are gene/protein names and p1 acts
on p2 in the interaction). Examples of these interactions are listed
in Table 2.
Knowledge Representation
To identify drug indications through automated reasoning, it is
important to properly represent our knowledge on basic drug
mechanism. This requires the formation of the logic facts for the
knowledge acquired from various sources as described in the
previous subsection. In addition, logic rules are used to represent the
properties of drug mechanism. We adopted a popular knowledge
representation language called AnsProlog [23,24] for the repre-
sentation of the logic facts and rules.
AnsProlog is a declarative language that is useful for reasoning,
including reasoning with incomplete information. One of the
advantages of using a declarative language is that we define what
the program should achieve and not how it should be achieved. It
is important to notice that AnsProlog is a declarative language
different from Prolog. While Prolog is a programming language
with roots in logic, it includes many non-logical features that are
not declarative, making it unsuitable for knowledge representation.
Here we give a brief introduction to the syntax of AnsProlog.
An AnsProlog rule is of the form:
l/l0, . . . ,lm,not lmz1, . . . ,not ln:
where lis are literals and not represents negation as failures. The
intuitive meaning of the above rule is that if it is known that literals
l0,..., lm are to be true and if lm+1,..., ln can assume to be false, then l
must be true. A literal is defined as either an atom or an atom
preceded by the symbol that indicates classical negation. If there is
no literal l in the head of a rule, then the rule is referred as
a constraint. On the other hand, if there are no literals in the body of
a rule, then the rule is referred as a fact, and its short hand of the
representation of a fact is simply the head literal itself. An answer
set program is composed of a set of AnsProlog rules, and the
interpretation of an answer set program is called answer sets.
Readers can refer to [25] for more details on the syntax and
semantics of AnsProlog.
Table 1. Different types of knowledge used in our approach and their sources.
Types of knowledge Sources
Drug-target interactions DrugBank
Oncogenes and tumor suppressors UniProt, Entrez Gene, CancerQuest
Genes involved in cancer-related biological processes Gene Ontology
Gene-disease relations Medline abstracts by text mining
Protein-protein interactions Medline abstracts by text mining
doi:10.1371/journal.pone.0040946.t001
Table 2. Examples of extracted gene-disease relationships and protein-protein interactions with their support evidences.
Evidences Extracted relationships
The results of our study demonstrate that AMACR expression is upregulated in
gastric cancer (PMID: 18787636)
,over-expressed AMACR, associated with, gastric cancer.
Therefore, inactivation of Rb protein by HPV 18 E7 protein may be associated with
carcinogenesis of small cell carcinoma (PMID:14506638)
,under-expressed RB1, associated with, small cell carcinoma.
Moreover, HER-2 expression was stimulated by EGF addition in young cells (PMID:8028398) ,EGF, induces, ERBB2.
Inhibition of PPARgamma activity by TNF-alpha is involved in pathogenesis of insulin
resistance (PMID: 18655773)
,TNF, inhibits, PPARG.
doi:10.1371/journal.pone.0040946.t002
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Logic Facts
Two basic types of logic facts are represented in our drug
mechanism domain: (i) entities and classes such as proteins and
drugs that are involved in drug mechanism; (ii) interactions such as
gene-disease relationships. The class protein is represented in the
form of protein(Prot), in which Prot is a variable for the class, and
protein(tp53) is an instance of the class protein. The entities and
their logic forms are shown in Table 3.
The class cancer-resisting biological process involves the
following instances of Gene Ontology terms:
N Negative regulation of cell proliferation (GO:0008285)
N Positive regulation of apoptosis (GO:0043065)
N Negative regulation of angiogenesis (GO:0016525)
On the other hand, the class cancer-promoting biological
process involves these instances:
N Positive regulation of cell proliferation (GO:0008284)
N Negative regulation of apoptosis (GO:0043066)
N Positive regulation of angiogenesis (GO:0045766)
For the interactions involved in the domain, they are
represented with the predicate interaction for drug-target and
protein-protein interactions and relation for gene-disease as well as
gene-biological process relations. For instance, the logic form of
the gene-disease relation ,over-expressed AMACR, associated
with, gastric cancer. is represented as relation(overexpressed(a-
macr), associated_with, gastric_cancer) while interaction(egf,
induces, erbb2) is the logic form for the protein-protein interaction
,EGF, induces, ERBB2., and EGF is the interactor of the
interaction that acts upon ERBB2, the interactee of the interaction.
A complete list of logic forms for the interactions is shown in
Table 4.
Logic Rules
In representing the process of drug mechanism, logic rules are
used to describe how a drug triggers the effect of the proteins based
on the acquired interactions. Through the effects of the proteins,
a series of steps eventually leads to the therapeutic relationship
between the drug and the corresponding disease. We represent
each triggering step on how a drug Dr affects the state of a protein
Prot in the form of trigger(Dr, Action, Prot, Step). Action is a class of
effects such as activates (a drug activating a protein) and inactivates (a
drug inhibiting a protein). Step is a variable indicating the order of
the triggering step in the series. For instance, trigger(moclobemide,
inactivates, maoa, 1) indicates that moclobemide inhibits the function
of MAOA in step 1.
The core idea of the representation of mechanism of actions is
to encode the pre- and post-conditions of interactions, also known
as the executability and direct effects of actions. Using the effect of
the activation of a tumor suppressor (denoted as Prot) as an
example, cancer is identified as an indication for drug Dr when
activation of the tumor suppressor is triggered by Dr previously.
This mechanism is captured by the following AnsProlog rule:
trigger Dr, treats, cancer, Sz1ð Þ/trigger Dr, activates, Prot, Sð Þ,
suppressor Protð Þ, drug Drð Þ, step Sð Þ:
The principles behind the representation of mechanism of drug
action are described below:
N Drug Dr triggers the inhibition (respectively activation) of protein
Prot when Dr acts as an antagonist (respectively an agonist) for
Prot. This is the initial step to trigger the mechanism.
N Drug Dr triggers the activation (respectively inactivation) of the
function of protein Prot2 when protein Prot1 has been activated
by Dr and the activated Prot1 increases (respectively decreases) the
expression of Prot2.
N Drug Dr is identified as a treatment for cancer when protein
Prot has been inhibited (respectively induced) by Dr and
overexpressed (respectively underexpressed) Prot is known to be
associated with cancer.
N Drug Dr is identified as a treatment for cancer when oncogene
Prot has been inhibited by Dr.
N Drug Dr is identified as a treatment for cancer when tumor
suppressor Prot has been activated by Dr.
N Drug Dr is identified as a treatment for cancer when protein
Prot, which is involved in cancer-promoting biological process,
has been inhibited by Dr.
N Drug Dr is identified as a treatment for cancer when protein
Prot, which is involved in cancer-resisting biological process,
has been activated by Dr.
A list of AnsProlog logic rules describing the actions and effects
involved in drug mechanism can be found in Tables S1 and S2 of
the supplementary information.
Table 3. Logic forms for the classes and entities involved in the drug mechanism domain.
Facts Logic forms Examples
Prot is a protein, e.g. P53 protein(Prot) protein(tp53)
Prot is an oncogene, e.g. EGFR oncogene(Prot) oncogene(egfr)
Prot is a tumor suppressor, e.g. P53 suppressor(Prot) suppressor(tp53)
Dr is a drug, e.g. moclobemide drug(Dr) drug(moclobemide)
Dise is a disease, e.g. depression disease(Dise) disease(depression)
Bp is a cancer-promoting biological process, e.g. positive
regulation of cell proliferation
cancer_promoting_bioprocess(Bp) cancer_promoting_bioprocess(pos_reg_cell_proliferation)
Bp is a cancer-resisting biological process, e.g. positive
regulation of apoptosis
cancer_resisting_bioprocess(Bp) cancer_resisting_bioprocess(pos_reg_apoptosis)
doi:10.1371/journal.pone.0040946.t003
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Reasoning
With the acquired facts in logic form and the drug mechanism
of actions described in logic rules, the next step is to define our
goal – find a series of steps that eventually identifies a possible drug
indication. Unlike semantic technologies such as SPARQL where
the user has to explicitly define the right kind of queries in order to
link up various sources of knowledge, the AnsProlog logic rules
defined in the previous section only describe the effects of actions
for the next step given the state of the current step and the logic
facts. It is the task of the reasoning component to link up various
sources and assign ordering of the steps that lead to a series of steps
for drug indication. Our expectation is that the inference has to
include: (i) a series of steps that involves a triggering step on how
a drug Dr can be used for the treatment of cancer in the form of
trigger(Dr, treats, cancer, S); (ii) the triggering step trigger(Dr, treats,
cancer, S) as the last step of the inference. To compute the answer
sets that infer drug indications, an AnsProlog solver called clingo
[26] is utilized to compute direct and indirect inferences based on
the logic rules and the acquired logic facts.
Scenarios
Two types of inferences can be generated by our method: direct
inference and indirect inference. Direct inference corresponds to
drug indications that are directly triggered by drug targets, while
drug targets play an indirect role in diseases in indirect inference.
We illustrate each of the steps involved in inferring alternative
drug indications for dipyridamole and tazarotene.
Example of a Direct Inference: Dipyridamole as
a Treatment for Leukemia
Dipyridamole is used to reduce blood clots through the
inhibition of adenosine deaminase [PubMed-Health: Dipyrida-
mole]. To find alternative indications for dipyridamole, the first
step of our method is to acquire the necessary knowledge such as
drug-target interactions and gene-disease relations. In this case,
the following facts were acquired:
N interaction(dipyridamole, inhibits, ada): dipyridamole acts as
an antagonist for adenosine deaminase (ADA) [Source:
DrugBank]
N relation(overexpressed(ada), associated_with, cancer): High
levels of adenosine deaminase (ADA) activity have been
associated with normal T cell differentiation and T cell disease,
such as acute lymphoblastic leukemia [Source: PMID:
6981287]
Dipyridamole is proposed as a potential treatment for cancer as
ADA can be inhibited by dipyridamole and overexpression of
ADA is associated with acute lymphoblastic leukemia. As of
September 2011, dipyridamole is under phase I clinical trial for
treatment of hepatic metastases from solid tumors [27].
N trigger(dipyridamole, inactivates, ada, 1)
N trigger(dipyridamole, treats, cancer, 2)
Figure 1 illustrates the steps involved in the direct inference of
drug indication for dipyridamole.
Table 4. Logic forms for the interactions involved in the drug mechanism domain.
Relations Logic forms
Drug Dr induces the activity of protein Prot interaction(Dr, induces, Prot)
Drug Dr inhibits the activity of protein Prot interaction(Dr, inhibits, Prot)
Protein Prot1 induces the activity of Protein Prot2 interaction(Prot1, induces, Prot2)
Protein Prot1 inhibits the activity of Protein Prot2 interaction(Prot1, inhibits, Prot2)
Overexpressed protein Prot is associated with disease Dise relation(overexpressed(Prot), associated_with, Dise)
Underexpressed protein Prot is associated with disease Dise relation(underexpressed(Prot), associated_with, Dise)
Protein Prot plays a role in biological process Bp relation(Prot, is_associated, Bp)
doi:10.1371/journal.pone.0040946.t004
Figure 1. A diagrammatic view of (a) direct and (b) indirect inferences for dipyridamole and tazarotene as novel cancer indications.
doi:10.1371/journal.pone.0040946.g001
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Example of an Indirect Inference: Tazarotene as
a Treatment for Cancer
Tazarotene is approved for the treatment of psoriasis and acne.
The facts below are acquired from different sources to identify
alternative indication of tazarotene.
N interaction(tazarotene, induces, rara): tazarotene acts as an
agonist for retinoic acid receptor alpha (RARA) [Source:
DrugBank]
N interaction(rara, inhibits, egfr): These results suggest that RAR
ligand-associated down-regulation of EGFR activity reduces
cell proliferation by reducing the magnitude and duration of
EGF-dependent ERK1/2 activation. [Source: PMID:
11788593]
N oncogene(efgr) [Source: CancerQuest]
With the acquired facts and the logic rules, the following steps in
the inference are triggered:
N trigger(tazarotene, activates, RARA, 1)
N trigger(tazarotene, inactivates, EGFR, 2)
N trigger(tazarotene, treats, cancer, 3)
The indirect inference generated by our method shows that
RARA can be activated by the agonist tazarotene. The activated
RARA inhibits EGFR expression, and the inhibition of the
oncogene EGFR can lead to cancer treatment. This inference is
illustrated in Figure 1(b). As of April 2009, a phase II trial is
currently underway to study the effectiveness of tazarotene in
treating patients with basal cell skin cancer. The study is estimated
to be completed by June 2013 [28].
Results
For the knowledge acquisition component, we first compiled
a list of drugs from DrugBank that contain information on their
targets and interaction types, i.e. whether a drug is an antagonist
or agonist for a target. This results in a list of 943 drugs that
constitute 1704 drug-target interactions. In addition, a list of 265
cancer-related genes was obtained from UniProt, Entrez Gene and
CancerQuest and another 1420 genes that are involved in cancer-
related biological processes were acquired from the Gene
Ontology. Together with 16816 protein-protein interactions and
25866 gene-disease relations extracted from the literature, these
form a knowledge base of facts that are relevant to the mechanism
of actions of drugs.
To assess the performance of our approach, our evaluation
involves two aspects: (i) whether the drug indications suggested by
our MOA-based approach are indeed the original indications of
the drugs, without the direct use of such information; (ii) whether
our suggested drug indications are currently under clinical trials
for the indications according to ClinicalTrials.gov. Among the 943
drugs that were obtained from DrugBank, 81 of them are
indicated as cancer drugs according to DrugBank. We also
downloaded the records of the clinical trials from http://
clinicaltrials.gov dated in December 2011. 289 drugs that do not
have cancer as their original indications are found to be currently
investigated as therapeutics for various types of cancers.
Table 5. Evaluation of the inferences using a list of 943 drugs based on original indication and clinical trials.
Cancer genes GO Text mining All
Cancer as original indication (81) 25 43 58 67 (82.7%)
Non-cancer drugs under clinical trials for cancer (289) 46 95 133 144 (49.8%)
Total inferences 171 335 455 507
% inferences confirmed to be cancer-related 41.5% 41.2% 42.0% 41.6%
doi:10.1371/journal.pone.0040946.t005
Figure 2. Treatment distribution for the 296 inferred drugs that neither have cancer as the original indication nor in clinical trials
for cancer.
doi:10.1371/journal.pone.0040946.g002
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Our method suggested 507 drugs that have the potential to be
used for cancer treatments. Among the suggested drug uses, 67 out
of 81 drugs (a recall of 82.7%) are indeed drugs with cancer as
their original indications. In addition, 144 out of 289 drugs (a
recall of 49.8%) are non-cancer drugs that are in clinical trials for
cancer. In other words, 211 out of the 507 inferred drug
indications are confirmed to be cancer-related. These results,
summarized in Table 5, show that our method is capable of
assigning correct drug indications. We also compared the
contribution in inferring drug indications among the various
different sources of knowledge, i.e. the use of cancer-related genes
(denoted as Cancer genes, genes involved in cancer-related biological
processes (GO) and relations extracted from literature (Text mining).
We found that the inferences generated based on each of the three
sources has about the same reliability in terms of the number of
inferences that are confirmed to be cancer-related. All three of
them are in the range of 41% to 42%, as illustrated in Table 5.
This shows that relations extracted by means of text mining can be
as reliable as other sources for inference of alternative indications.
With the broad coverage of relations obtained from text mining,
findings for alternative indications can be more comprehensive
than solely using manual curated sources.
We first performed analysis on the known cancer drugs that
have been missed in our prediction. As indicated in Table 5, 67 of
the 81 known cancer drugs are correctly predicted to be drugs for
cancer treatment by our system. Among the 14 missed cancer
drugs, interactions related to the drug targets of 8 of these cancer
drugs cannot be found in the knowledge sources that were used by
our system. The other 6 include contradictory interactions for the
drugs and their drug targets within our knowledge sources. For
example, PNP is one of the drug targets for cladribine, and it is
known to be an agonist for PNP according to DrugBank.
However, PNP is involved in the positive regulation of cell
proliferation (GO:0042102) based on Gene Ontology. Activated
PNP would lead to increase rate of cell proliferation, which is not
ideal to be used for cancer treatment according to our system.
Details of the analysis can be found in Table S3 of the
supplementary information.
We further characterize the remaining 296 drugs that do not
have cancer as original indications nor found to be in clinical trials
for cancer. We first categorized the drugs in major treatment
categories, and found that 17.7% of these drugs are currently used
for treatments of inflammation. Links between Inflammation and
tumor progression has been previously established in literature
[29]. Another major category is the treatment of cardiovascular
diseases constituting about 21.2%. The distribution of the main
disease types is summarized in Figure 2.
Evaluation of Text Mining Results
The inference of new indications for drugs largely depends on
the correctness of the interactions extracted from the literature.
Here we performed evaluation for the extraction of gene-disease
relations and protein-protein interactions using various corpora.
We adopted a corpus of gene-disease relations annotated from
5720 GeneRIF sentences [30] using the altered expression category
for the evaluation of our gene-disease relations. The altered
expression category contains 1044 gene-disease relations that
correspond to the change of gene expression and its relations with
diseases. In our evaluation we focused on relations that indicate
overexpression or underexpression of genes to reflect our model of
drug mechanism, and this forms a subset of 674 gene-disease
relations. Our evaluation indicates that the extracted gene-disease
relations result in a precision of 93.61%. The results of the
evaluation are summarized in Table 6. Further analysis revealed
that 50% of the incorrect gene-disease relations (i.e. false positives)
are due to negation and another 28% of the false positives involved
incorrect interactors or interactees in the extracted relations.
Examples of incorrectly extracted gene-disease relations are shown
in Table 7.
For protein-protein interactions, we performed the evaluation
using the BioInfer corpus [31], one of the commonly used corpora
for the evaluation of protein-protein interaction extraction. The
BioInfer corpus contains 1100 sentences from Medline abstracts
annotated with various biological relationships that include 425
protein-protein interactions. In this evaluation we focused on
interactions that indicate the increase or decrease of the expression
of a protein by another protein, and this forms a subset of 170
protein-protein interactions. Our evaluation indicates that the
extracted protein-protein interactions results in a precision of
52.63%. The results of the evaluation are summarized in Table 6.
Further analysis revealed that 50% of the false positives are due to
incorrect interactee and another 27.8% of the false positives
involved incorrect interactors. The rest of the false positives
include both incorrect interactors and interactees such that the
pair of entities has no actual relation to each other.
Table 6. Performance of the extraction of gene-disease
relations (GDRs) and protein-protein interactions (PPIs).
GDRs
(Bundschus corpus) PPIs (Bioinfer corpus)
True Positives (TP) 205 20
False Positives (FP) 14 18
False Negatives (FN) 469 150
Precision 93.61% 52.63%
Recall 30.42% 11.76%
F-measure 45.91% 19.23%
doi:10.1371/journal.pone.0040946.t006
Table 7. Examples of incorrectly extracted gene-disease relations due to negation (E1) and wrong interactor (E2).
Gene-disease relation Sentence
E1 ,overexpressed CCR7, associated with, lymphocyte-predominant
Hodgkin disease.
Up-regulation of CCR7 in classical but not in lymphocyte-predominant Hodgkin disease
correlates with ….
E2 ,overexpressed Bcl-2, associated with, acute myelogenous
leukemia.
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/
MAPK pathways in acute myelogenous leukemia.
doi:10.1371/journal.pone.0040946.t007
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Discussion
Automated reasoning is a powerful technique in artificial
intelligence that enables knowledge inference based on domain
knowledge and multiple data sources. In the biomedical domain
the capabilities of reasoning have been demonstrated in the
synthesis of pharmacokinetic pathways [32] and identification of
drug-drug interactions [33]. Here we demonstrate the capability of
automated reasoning to another important aspect of the drug
development process – identification of novel drug indications for
existing drugs. Unlike typical literature-based approaches that
produce large network of biological entities based on coocur-
rences, our approach takes interaction types and directionality into
consideration so that the search space is more computationally
feasible. In addition, the hypotheses generated by our approach
reflect the mechanism of action of drugs as well as the key
mechanisms of cancer. This eliminates the time-consuming
process of using network visualization to sift through the large
network of interactions manually to identify novel drug indica-
tions. Our results showed that a significant number of drugs
predicted by our method indeed have cancer as the original
indication. Some of our findings even showed that the drugs are
indeed currently under clinical trials for cancer.
While our method is capable of making not only correct but also
novel drug indications, our current approach is limited to the
identification of cancer treatment. In addition, the false positives
for the relations obtained from text mining may contribute to the
overall false positives in our predictions. Further improvement of
our text mining method is needed to produce even more reliable
inferences. To predict alternative indications for other disease
areas, the domain knowledge has to be extended to encode the
mechanism of other kinds of diseases and signaling pathways.
Another future direction is to capture chemical structure in-
formation of drug compounds in order to identify alternative drug
indications.
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